MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models-Reference-Cited by-同舟云学术

MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models

Published:2013-11 Issue:10 Volume:24 Page:1030-1038
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Gu Juan J.,Hernandez-Ilizaliturri Francisco J.,Mavis Cory,Czuczman Natalie M.,Deeb George,Gibbs John,Skitzki Joseph J.,Patil Ritesh,Czuczman Myron S.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference14 articles.

1. The ubiquitin-proteasome pathway: on protein death and cell life.;Ciechanover;EMBO J,1998

2. Protein degradation and protection against misfolded or damaged proteins.;Goldberg;Nature,2003

3. The proteasome: a suitable antineoplastic target.;Adams;Nat Rev Cancer,2004

4. Next-generation proteasome blockers promise safer cancer therapy.;Mullard;Nat Med,2012

5. Hematological cancer in 2011: new therapeutic targets and treatment strategies.;Cramer;Nat Rev Clin Oncol,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of GATAD1 regulating the SRRM2 gene on recurrence of thyroid tumor and its molecular mechanism;Gland Surgery;2022-12

2. Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma;Current Cancer Drug Targets;2019-12-20

3. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution;Cancer Letters;2019-01

4. The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma;Blood Advances;2018-12-10

5. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment;Nature Medicine;2018-01-15